Announcement PDF ASX Announcement – 10 June 2025 RESONANCE LAUNCHES INVESTORHUB PORTAL TO BOOST INVESTOR ENGAGEMENT Resonance Health Ltd (ASX: RHT) (Resonance or Company) advises that it has launched ‘InvestorHub’, a new initiative for dedicated investor and market participant engagement. InvestorHub provides shareholders and other interested parties the opportunity to view the Company’s ASX announcements, shareholder news, and key updates - all in one place. Resonance is entering an exciting new phase as it continues to rapidly and profitably scale up its operations with the execution of its strategy to drive growth in its 3-business focus areas; (i) Clinical Trial Management CRO Services (Resonance Clinical), (ii) Software-as-a-Medical Device Image Analysis Services (SaMD), and (iii) Clinical Trial Site Services (TrialsWest). There are several exciting near-term growth drivers in the business: • Completion of the extended proof of concept trial (EPoC) and early commercialisation of a non-invasive MRI Liver Fibrosis SaMD; • Additional clinical trial wins for Resonance Clinical, and • Continued organic and acquisitive expansion of the TrialsWest network. The Company will regularly upload new content to the hub, such as videos, key project news, and other updates that may be of interest to market participants. Shareholders and other interested parties are invited to create an account and join the InvestorHub initiative via the sign-up link below. Resonance encourages investors to post questions and feedback through the Q&A function accompanying the content uploaded by the Company, to engage with the Company’s leadership team and to gain a better understanding of the Company’s operations and updates. Resonance Health CEO, Mr. Andrew Harrison, said of the new hub: “Resonance Health is excited to launch ‘InvestorHub’ to better communicate and interact with our shareholders and interested market participants. We have a year of growth ahead of us as we expand our global partnerships and innovations. We look forward to shareholders coming on that journey with us and to welcoming new shareholders. InvestorHub provides a centre for our shareholders to stay up to date and receive the latest market announcements and news directly from us.” To watch Mr Harrison’s introduction to the new platform, please visit the Company’s InvestorHub here: https://investors.resonancehealth.com/link/0PQQbP Further Information https://investors.resonancehealth.com Andrew Harrison – Chief Executive Officer E: andrewh@resonancehealth.com P: +61 (0)8 9286 5300 Resonance Health Ltd ABN: 96 006 762 492 141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com About Resonance Health Resonance Health is an Australian healthcare technology and services company. The Company’s services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: § FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. § FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®. § HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease. § HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease. § LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat. § CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared. The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. The Company also operates Clinical Trial Management (CRO Services) and Clinical Trial Site (TrialsWest) businesses that cater to global clinical trial customers. Page 2